Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,580.06
(
0.22%
)
US TECH 100
29,506.00
(
0.28%
)
Dow Jones
51,032.46
(
0.72%
)
Brent Oil
92.85
(
1.63%
)
Bitcoin
73,401.32
(
-0.21%
)
News Focus
News Focus
Post# of 257662
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123040
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 40501

Wednesday, 01/10/2007 7:16:25 PM

Wednesday, January 10, 2007 7:16:25 PM

Post# of 257662
Lucentis (55% penetration of new AMD patients) and off-label Avastin had close to 100% penetration of the U.S. wet AMD market between them during 4Q06. In other words, almost everyone in the U.S. with diagnosed clinically-relevant AMD is getting treatment, and Macugen and Visudyne have already become non-factors. (Source: Today’s DNA CC)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today